Axxcess Wealth Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$460K Hold
4,725
– – 0.02% 594
2026
Q2
$424K Buy
+4,725
New +$389K 0.01% 762
2026
Q1
– Sell
-4,725
Closed -$388K – 801
2025
Q4
$388K Hold
4,725
– – 0.01% 771
2025
Q3
$330K Hold
4,725
– – 0.01% 732
2025
Q2
$303K Sell
4,725
-550
-10% -$34.1K 0.01% 712
2025
Q1
$335K Hold
5,275
– – 0.01% 651
2024
Q4
$351K Sell
5,275
-67
-1% -$4.62K 0.01% 630
2024
Q3
$373K Hold
5,342
– – 0.01% 631
2024
Q2
$346K Hold
5,342
– – 0.01% 612
2024
Q1
$346K Hold
5,342
– – 0.01% 632
2023
Q4
$352K Buy
+5,342
New +$311K 0.01% 601

Other funds holding PBE

Axxcess Wealth Management's PBE Position: Q3 2026 in Review

Axxcess Wealth Management held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q3 2026 at 4,725 shares worth $460K. The position accounts for 0.02% of the portfolio, ranked #594.

Axxcess Wealth Management first reported a position in PBE in Q4 2023 and has held it in 11 quarters since. 55 funds tracked by Wall St. Rank hold PBE as of Q3 2026.

  • Axxcess Wealth Management held 4,725 shares of Invesco Biotechnology & Genome ETF worth $460K as of Q3 2026.
  • Axxcess Wealth Management left its Invesco Biotechnology & Genome ETF share count unchanged in Q3 2026.
  • Invesco Biotechnology & Genome ETF made up 0.02% of Axxcess Wealth Management's portfolio in Q3 2026, its #594 holding.
  • Axxcess Wealth Management first reported a position in Invesco Biotechnology & Genome ETF in Q4 2023 and has held it in 11 quarters since.
  • 55 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.

Based on Axxcess Wealth Management's 13F filing for Q3 2026, filed 21 Oct 2026.